Skip to main content
SpringerLink
Log in
Book cover

Clinical Approach to Infection in the Compromised Host pp 355–377Cite as

Viral Hepatitis in the Compromised Host

  • Chapter

  • 69 Accesses

Abstract

Five categories of viral hepatitis have been recognized: hepatitis A, hepatitis B, hepatitis C (non-A, non-B hepatitis), hepatitis B-associated delta hepatitis (hepatitis D), and hepatitis E. Although all five have the potential to produce similar illnesses, clinical severity and outcome as well as the contribution of immunologic mechanisms to the clinical expression of infection and illness appear to differ among the various types. Observations of viral hepatitis in immunosuppressed persons have taught us important lessons about the biology of these viral agents, on the one hand, and about the approach to immunologically compromised patients with hepatitis, on the other. Unlike susceptibility of immunosuppressed persons to opportunistic infections, susceptibility to viral hepatitis per se is not increased in the immunosuppressed; however, because patients with immunologic derangements are very likely to require transfusions of blood products, the frequency of viral hepatitis in this group of patients is increased. In addition, severity of acute illness, likelihood of chronic infection, infectivity, serologie responsiveness, and the early and late consequences of chronic infection differ distinctly between immunocompetent and immunosuppressed hosts.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Szmuness W, Purcell RH, Dienstag JL, et al: Antibody to hepatitis A antigen in institutionalized mentally retarded patients. JAMA 237: 1702–1705, 1977.

    PubMed  CAS  Google Scholar 

  2. Szmuness W, Dienstag JL, Purcell RH, et al: Hepatitis type A and hemodialysis: A seroepidemiologic study in 15 U.S. centers. Ann Intern Med 87: 8–12, 1977.

    PubMed  CAS  Google Scholar 

  3. Balayan MS: HEV infection: Historical perspectives, global epidemiology, and clinical features in Hollinger FB, Lemon SM, Margolis H (eds): Viral Hepatitis and Liver Disease. Baltimore, Williams & Wilkins, 1991, pp 498–501.

    Google Scholar 

  4. Popper H, Thung SN, Gerber MA, et al: Histologic studies of severe delta agent infection in Venezuelan Indians. Hepatology 3: 906–912, 1983.

    PubMed  CAS  Google Scholar 

  5. Friedman LS, Dienstag JL: The disease and its pathogenesis, in Gerety RJ (ed): Hepatitis A. New York, Academic Press, 1984, pp 55–79.

    Google Scholar 

  6. Dienstag JL, Bhan AK, Klingenstein RJ, et al: Immunopathogenesis of liver disease associated with hepatitis B in Szmuness W, Alter HJ, Maynard JE (eds): Viral Hepatitis—1981 International Symposium. Philadelphia, Franklin Institute, 1982, pp 221–236.

    Google Scholar 

  7. Dienstag JL: Immunologic mechanisms in chronic viral hepatitis, in Vyas GN, Dienstag JL, Hoofnagle JH (eds): Viral Hepatitis and Liver Disease. New York, Grune & Stratton, 1984, pp 135–166.

    Google Scholar 

  8. Blumberg BS, Sutnick AI, London WT: Australia antigen as a hepatitis virus: Variation in host response. Am J Med 48: 1–8, 1970.

    PubMed  CAS  Google Scholar 

  9. Blumberg BS, Gerstley BJS, Hungerford DA, et al: A serum antigen (Australia antigen) in Down’s syndrome, leukemia and hepatitis. Ann Intern Med 66: 924–931, 1967.

    PubMed  CAS  Google Scholar 

  10. Blumberg BS, Sutnick AI, London WT: Hepatitis and leukemia: Their relation to Australia antigen. Bull NY Acad Med 44: 1566–1586, 1968.

    CAS  Google Scholar 

  11. Szmuness W, Harley EJ, Ikram H, et al: Sociodemographic aspects of the epidemiology of hepatitis B, in Vyas GN, Cohen SN, Schmid R (eds): Viral Hepatitis. Philadelphia, Franklin Institute, 1978, pp 297–320.

    Google Scholar 

  12. Markenson JA, Gerety RJ, Hoofhagle JH, et al: Effects of cyclophosphamide on hepatitis B virus infection and challenge in chimpanzees. J Infect Dis 131: 79–87, 1975.

    PubMed  CAS  Google Scholar 

  13. Galbraith RM, Eddieston ALWF, Williams R, et al: Fulminant hepatic failure in leukemia and choriocarcinoma related to withdrawal to cytotoxic drug therapy. Lancet 2: 528–530, 1975.

    PubMed  CAS  Google Scholar 

  14. Sagnelli E, Manzillo G, Maio G, et al: Serum levels of hepatitis B surface and core antigens during immunosuppressive treatment of HBsAg-positive chronic active hepatitis. Lancet 2: 395–397, 1980.

    PubMed  CAS  Google Scholar 

  15. Scullard GH, Smith CI, Merigan TC, et al: Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B. Gastroenterology 81: 987–991, 1981.

    PubMed  CAS  Google Scholar 

  16. Villa E, Theodossi A, Portmann B, et al: Reactivation of hepatitis B virus infection in two patients: Immunofluorescence studies of liver tissue. Gastroenterology 80: 1048–1053, 1981.

    PubMed  CAS  Google Scholar 

  17. Reed WD, Eddleston ALWF, Cullens H, et al: Infusion of hepatitis B antibody in antigen-positive active chronic hepatitis. Lancet 2: 1347–1351, 1975.

    Google Scholar 

  18. Kohler PF, Trembath J, Merrill DA, et al: Immunotherapy with antibody, lymphocytes and transfer factor in chronic hepatitis B. Clin Immunol Immunopathol 2: 465–471, 1974.

    Google Scholar 

  19. Thomas HC, Chadwick RG, Jain S, et al: Levamisole therapy for HBs antigen positive chronic liver disease. Gastroenterology 73: A52, 1977 (abstr.).

    Google Scholar 

  20. Jain S, Thomas HC, Sherlock S: Transfer factor in the attempted treatment of patients with HBsAg-positive chronic liver disease. Clin Exp Immunol 30: 10–15, 1977.

    PubMed  CAS  Google Scholar 

  21. Good RA, Page AR: Fatal complications of virus hepatitis in two patients with agammaglobulinemia. Am J Med 29: 804–810, 1960.

    PubMed  CAS  Google Scholar 

  22. Mondelli M, Mieli Vergani G, Alberti A, et al: Specificity of T lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection: Evidence that T cells are directed against HBV core antigen expressed on hepatocytes. J Immunol 129: 2773–2778, 1982.

    PubMed  CAS  Google Scholar 

  23. Naumov NV, Mondelli M, Alexander GJM, et al: Relationship between expression of hepatitis B virus antigens in isolated hepatocytes and autologous lymphocyte cytotoxicity in patients with chronic hepatitis B virus infection. Hepatology 4: 63–68, 1984.

    PubMed  CAS  Google Scholar 

  24. Ceuppens JL, Stevens E, Fevery J, et al: Complete recovery from hepatitis B and associated hemolysis in a patient with underlying T-cell deficiency. Gastroenterology 86: 937–940, 1984.

    PubMed  CAS  Google Scholar 

  25. Romet-Lemonne JL, McLane MF, Elfassi E, et al: Hepatitis B virus infection in cultured human lymphoblastoid cells. Science 221: 667–669, 1983.

    PubMed  CAS  Google Scholar 

  26. Choo Q-L, Kuo G, Weiner AJ, et al: Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244: 359–362, 1989.

    PubMed  CAS  Google Scholar 

  27. Kuo G, Choo Q-L, Alter HJ, et al: An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 244: 362–364, 1989.

    PubMed  CAS  Google Scholar 

  28. Esteban JI, Esteban R, Viladomio L, et al: Hepatitis C virus antibodies among risk groups in Spain. Lancet 2: 294–297, 1989.

    PubMed  CAS  Google Scholar 

  29. Blumberg BS, Alter HJ, Visnich S: A “new” antigen in leukemia sera. JAMA 191: 541–546, 1965.

    PubMed  CAS  Google Scholar 

  30. Goldblum SE, Reed WP: Host defenses and immunologic alterations associated with chronic hemodialysis. Ann Intern Med 93: 597–613, 1980.

    PubMed  CAS  Google Scholar 

  31. Agarwal SS, Blumberg BS, Gerstley BS, et al: DNA polymerase activity as an index of lymphocyte stimulation: Studies in Down’s syndrome. J Clin Invest 49: 161–169, 1970.

    PubMed  CAS  Google Scholar 

  32. Boughton CR, Hawkes RA, Schroeter DR, et al: The epidemiology of hepatitis B in a residential institution for the mentally retarded. Aust NZ J Med 6: 521–529, 1976.

    CAS  Google Scholar 

  33. Hawkes RA, Boughton CR, Schroeter DR, et al: Hepatitis B infection in institutionalized Down’s syndrome inmates: A longitudinal study with five hepatitis B virus markers. Clin Exp Immunol 40: 478–486, 1980.

    PubMed  CAS  Google Scholar 

  34. Madden DL, Dietzman DE, Matthew EB, et al: Epidemiology of hepatitis B virus in an institution for mentally retarded persons. Am J Ment Defic 80: 369–375, 1976.

    PubMed  CAS  Google Scholar 

  35. Chaudhary RK, Perry E, Cleary TE: Prevalence of hepatitis B infection among residents of an institution for the mentally retarded. Am J Epidemiol 105: 123–126, 1977.

    PubMed  CAS  Google Scholar 

  36. Szmuness W, Pick R, Prince AM: The serum hepatitis virus specific antigen (SH): A preliminary report of epidemiologic studies in an institution for the mentally retarded. Am J Epidemiol 92: 51–61, 1970.

    PubMed  CAS  Google Scholar 

  37. Hollingsworth DR, Hollingsworth JW, Roeckel I, et al: Immunologic reactions and Australia antigenemia in Down’s syndrome. J Chronic Dis 27: 483–490, 1974.

    PubMed  CAS  Google Scholar 

  38. Szmuness W, Neurath AR, Stevens CE, et al: Prevalence of hepatitis B “e” antigen and its antibody in various HBsAg carrier populations. Am J Epidemiol 113: 113–121, 1981.

    PubMed  CAS  Google Scholar 

  39. Garibaldi RA, Forrest JN, Bryan JA, et al: Hemodialysisassociated hepatitis. JAMA 225: 384–389, 1973.

    PubMed  CAS  Google Scholar 

  40. Snydman DR, Bryan JA, Hanson B: Hemodialysis-associated hepatitis in the United States—1972. J Infect Dis 132: 109–113, 1975.

    PubMed  CAS  Google Scholar 

  41. Szmuness W, Prince AM, Grady GF, et al: Hepatitis B infection: A point-prevalence study in 15 US hemodialysis centers. JAMA 227: 901–906, 1974.

    PubMed  CAS  Google Scholar 

  42. Centers for Disease Control: Hepatitis—Control measures for hepatitis B in dialysis centers. Viral hepatitis investigations and control series. U.S. Department of Health, Education and Welfare, Phoenix, November 1977, pp 1-9.

    Google Scholar 

  43. Szumness W: Large-scale efficacy trials of hepatitis B vaccines in the USA: Baseline data and protocols. J Med Virol 4: 327–340, 1979.

    Google Scholar 

  44. Sengar DPS, Rashid A, McLeish WA, et al: Hepatitis B surface antigen (HBsAg) infection in a hemodialysis unit. II. Factors affecting host immune response to HBsAg. Can Med Assoc J 113: 945–948, 1975.

    PubMed  CAS  Google Scholar 

  45. London WT, Drew JS, Lustbader ED, et al: Host responses to hepatitis B infection in patients in a chronic hemodialysis unit. Kidney Int 12: 51–58, 1977.

    PubMed  CAS  Google Scholar 

  46. Snydman DS, Bregman D, Bryan JA: Hemodialysis-associated hepatitis in the United States, 1974. J Infect Dis 135: 687–691, 1977.

    Google Scholar 

  47. Ribot S, Rothstein M, Goldblat M, et al: Duration of hepatitis B surface antigenemia (HBsAg) in hemodialysis patients. Arch Intern Med 139: 178–180, 1979.

    PubMed  CAS  Google Scholar 

  48. Gahl GM, Hess G, Arnold W, et al: Hepatitis B virus markers in 97 long-term hemodialysis patients. Nephron 24: 58–63, 1979.

    PubMed  CAS  Google Scholar 

  49. Beorchia S, Trepo C, Betuel H, et al: Interest of HbeAg in the study of immunogenetic factors influencing HBV infection in hemodialysed and kidney transplanted patients, in Touraine JL, Traeger J, Betuel H, et al (eds): Transplantation and Clinical Immunology. Amsterdam, Excerpta Medica, 1979, vol 10, pp 44–49.

    Google Scholar 

  50. Snydman DR, Bryan JA, Macon EJ, et al: Hemodialysisassociated hepatitis: Report of an epidemic with further evidence on mechanisms of transmission. Am J Epidemiol 104: 563–570, 1976.

    PubMed  CAS  Google Scholar 

  51. Garibaldi RA, Hatch FE, Bisno AL, et al: Nonparenteral serum hepatitis: Report of an outbreak. JAMA 220: 963–966, 1972.

    PubMed  CAS  Google Scholar 

  52. Coughlin GP, Van Deth AG, Disney APS, et al: Liver disease and the e antigen in HBsAg carriers with chronic renal failure. Gut 21: 118–122, 1980.

    PubMed  CAS  Google Scholar 

  53. Degott C, Degos F, Jungers P, et al: Relationship between liver histopathological changes and HBsAg in 111 patients treated by long-term hemodialysis. Liver 3: 377–384, 1983.

    PubMed  CAS  Google Scholar 

  54. Jungers P, Naret C, Degott C, et al: Histological and immunological survey of chronic active hepatitis in 650 hemodialyzed patients, in Touraine JL, Traeger J, Betuel H, et al (eds): Transplantation and Clinical Immunology. Amsterdam, Excerpta Medica, 1979, vol 10, pp 38–43.

    Google Scholar 

  55. Galbraith RM, Dienstag JL, Purcell RH, et al: Non-A, non-B hepatitis associated with chronic liver disease in a hemodialysis unit. Lancet 1: 951–953, 1979.

    PubMed  CAS  Google Scholar 

  56. Galbraith RM, Portmann B, Eddieston ALWF, et al: Chronic liver disease developing after outbreak of HBsAg-negative hepatitis in haemodialysis unit. Lancet 2: 886–890, 1975.

    PubMed  CAS  Google Scholar 

  57. Marmion BP, Burrell CJ, Tonkin RW, et al: Dialysis-associated hepatitis in Edinburgh, 1969-1978. Rev Infect Dis 4: 619–637, 1982.

    PubMed  CAS  Google Scholar 

  58. Coursaget P, Maupas P, Dubois F, et al: Hepatitis non-A, non-B chez six malades hemodialyses. Nouv Presse Med 7: 3515–3519, 1978.

    Google Scholar 

  59. Mery JP, Simon N, Courouce AM: Hepatite non-A, non-B chez les hemodialyses chroniques: 5 observations. Nouv Presse Med 8: 3973, 1979.

    CAS  Google Scholar 

  60. Koretz RL, Stone O, Brezina M, et al: Chronic hepatitis in the dialysis unit: Etiologic considerations. Gastroenterology 78: 1198, 1980.

    Google Scholar 

  61. Dienstag JL, Stevens CE, Szmuness W: The epidemiology of non-A, non-B hepatitis: Emerging patterns in Gerety JR (ed): Non-A, non-B Hepatitis. New York, Academic Press, 1981, pp 119–137.

    Google Scholar 

  62. Simon N, Mery JP, Trepo C, et al: A non-A, non-B hepatitis epidemic in a HB antigen-free hemodialysis unit. Demonstration of serological markers of non-A, non-B virus. Proc Eur Dial Transplant Assoc 17: 173–178, 1980.

    PubMed  CAS  Google Scholar 

  63. Avram MM, Feinfeld DA, Gan AC: Non-A, non-B hepatitis: A new syndrome in uraemic patients. Proc Eur Dial Transplant Assoc 16: 141–147, 1979.

    PubMed  CAS  Google Scholar 

  64. Zeldis JB, Dopner TA, Kuramoto IK, et al: The prevalence of hepatitis C virus antibodies among hemodialysis patients. Ann Intern Med 112: 958–960, 1990.

    PubMed  CAS  Google Scholar 

  65. Schlipköter V, Roggendorf M, Ernst G, et al: Hepatitis C virus antibodies in haemodialysis patients. Lancet 335: 1409, 1990.

    Google Scholar 

  66. Tamura I, Kobayashi Y, Koda T, et al: Hepatitis C virus antibodies in haemodialysis patients. Lancet 335: 1409, 1990.

    Google Scholar 

  67. Yamaguchi K, Nishimura Y, Fukuoka N, et al: Hepatitis C virus antibodies in haemodialysis patients. Lancet 335: 1409–1410, 1990.

    Google Scholar 

  68. Gilli P, Moretti M, Sofrritti S, et al: Anti-HCV positive patients in dialysis units?. Lancet 336: 243–244, 1990.

    Google Scholar 

  69. Mondelli MU, Cristina G, Filice G, et al: Anti-HCV positive patients in dialysis units?. Lancet 336: 224, 1990.

    Google Scholar 

  70. Wolf JL, Perkins HA, Schreeder MT, et al: The transplanted kidney as a source of hepatitis B infection. Ann Intern Med 91: 412–413, 1979.

    PubMed  CAS  Google Scholar 

  71. Lutwick LI, Sywassink JM, Corry RJ, et al: The renal transplant as a source of hepatitis B virus (HBV). Clin Res 29: 258A, 1981 (abstract).

    Google Scholar 

  72. Degos F, Degott C, Bedrossian J, et al: Is renal transplantation involved in post-transplantation liver disease? A prospective study. Transplantation 29: 100–102, 1980.

    PubMed  CAS  Google Scholar 

  73. Toussaint C, Thiry L, Kinnaert P, et al: Prognostic significance of hepatitis B antigenemia in kidney transplantation. Nephron 17: 335–342, 1976.

    PubMed  CAS  Google Scholar 

  74. Luby JP, Vurnett W, Hull AR, et al: Relationship between cytomegalovirus and hepatic function abnormalities in the period after renal transplant. J Infect Dis 129: 511–518, 1974.

    PubMed  CAS  Google Scholar 

  75. Kaiser L, Kelly TJ, Patterson MJ, et al: Hepatitis B surface antigen in urine of renal transplant recipients. Ann Intern Med 94: 783–784, 1981.

    PubMed  CAS  Google Scholar 

  76. Mayor GH, Kelly TJ, Hourani MR, et al: Intermittent hepatitis B surface antigenuria in a renal transplant recipient. Am J Med 68: 305–307, 1980.

    PubMed  CAS  Google Scholar 

  77. Nagington J, Cossart YE, Cohen BJ: Reactivation of hepatitis B after transplantation operations. Lancet 1: 558–560, 1977.

    PubMed  CAS  Google Scholar 

  78. Dusheiko G, Song E, Bowyer S, et al: Natural history of hepatitis B virus infection in renal transplant recipients—A fifteen-year follow-up. Hepatology 3: 330–336, 1983.

    PubMed  CAS  Google Scholar 

  79. London WT, Drew JS, Blumberg BS, et al: Association of graft survival with host response to hepatitis B infection in patients with kidney transplants. N Engl J Med 296: 241–244, 1977.

    PubMed  CAS  Google Scholar 

  80. London WT, Jarvinen H, Jasko L, et al: Hepatitis B virus infection in kidney transplant recipients, in Bianchi L, Gerok W, Sickinger K, et al (eds): Virus and the Liver. Lancaster, MTP Press, 1980, pp 267–276.

    Google Scholar 

  81. Jarvinen H, Shofer FS, Burke JF, et al: Antibody to hepatitis B surface antigen and kidney graft survival. Transplant Proc 15: 1094–1098, 1983.

    Google Scholar 

  82. Toussaint C, Cappel R, Veereerstraten P, et al: Graft survival and response to hepatitis-B virus in kidney recipients. Transplant Proc 11: 89–92, 1979.

    PubMed  CAS  Google Scholar 

  83. Pirson Y, Alexandre GPJ, van Ypersele de Strihou C: Long-term effect of HBs antigenemia on patient survival after renal transplantation. N Engl J Med 296: 194–196, 1977.

    PubMed  CAS  Google Scholar 

  84. Hillis WD, Hillis A, Walker WG: Hepatitis B surface antigenemia in renal transplant recipients: Increased mortality risk. JAMA 242: 329–332, 1979.

    PubMed  CAS  Google Scholar 

  85. Chatterjee SN, Payne JE, Bischell MD, et al: Successful renal transplantation in patients positive for hepatitis B antigen. N Engl J Med 291: 62–65, 1974.

    PubMed  CAS  Google Scholar 

  86. Berne TV, Fitzgibbons TJ, Silberman H: The effect of hepatitis B antigenemia on long-term success and hepatic disease in renal transplantation. Transplantation 24: 412–415, 1977.

    PubMed  CAS  Google Scholar 

  87. Fine RN, Malekzadeh MH, Pennisi AJ, et al: HBs antigenemia in renal allograft recipients. Ann Surg 185: 411–416, 1977.

    PubMed  CAS  Google Scholar 

  88. Ponticelli C, De Vecchi A, Cantaluppi A, et al: Hepatitis and renal transplants (letter). N Engl J Med 296: 1170, 1977.

    Google Scholar 

  89. Rashid A, Sengar D, Couture R, et al: Hepatitis and renal transplants (letter). N Engl J Med 296: 1170–1171, 1988.

    Google Scholar 

  90. Hillis WD, Hillis A, Bias WB, et al: Association of hepatitis B surface antigenemia with HLA locus B specificities. N Engl J Med 296: 1310–1314, 1977.

    PubMed  CAS  Google Scholar 

  91. Opelz G, Terasaki PI: Graft survival rates and HLA antigen frequencies in renal cadaver transplant recipients with hepatitis B antigenemia. Transplantation 25: 159–161, 1978.

    PubMed  CAS  Google Scholar 

  92. Parfrey PS, Forbes RDC, Hutchinson TA, et al: The clinical and pathological course of hepatitis B liver disease in renal transplant recipients. Transplantation 37: 461–466, 1984.

    PubMed  CAS  Google Scholar 

  93. Schroter GPJ, Weill R III, Perm I, et al: Hepatocellular carcinoma associated with chronic hepatitis B virus infection after kidney transplantation (letter). Lancet 2: 381–382, 1982.

    PubMed  CAS  Google Scholar 

  94. Anuras S, Piros J, Bonney WW, et al: Liver disease in renal transplant recipients. Arch Intern Med 137: 42–48, 1977.

    PubMed  CAS  Google Scholar 

  95. Strom TB: Hepatitis B, transfusions, and renal transplantation-five years later (editorial). N Engl J Med 307: 1141–1142, 1982.

    PubMed  CAS  Google Scholar 

  96. Berne TV, Chatterjee SN, Craig JR, et al: Hepatic dysfunction in recipients of renal allografts. Surg Gynecol Obstet 141: 171–175, 1975.

    PubMed  CAS  Google Scholar 

  97. Mozes MF, Ascher NL, Balfour HHJ, et al: Jaundice after renal allotransplantation. Ann Surg 188: 783–790, 1978.

    PubMed  CAS  Google Scholar 

  98. Ware AJ, Luby JP, Hollinger B, et al: Etiology of liver disease in renal-transplant patients. Ann Intern Med 91: 364–371, 1979.

    PubMed  CAS  Google Scholar 

  99. Alvarez V, Plaza JJ, Carreno V, et al: Viral infections and liver damage in renal transplant patients. Gastroenterology 79: 1001, 1980 (abstract).

    Google Scholar 

  100. Fennell RS III, Andres JM, Pfaff WW, et al: Liver dysfunction in children and adolescent during hemodialysis and after renal transplantation. Pediatrics 67: 855–861, 1981.

    PubMed  Google Scholar 

  101. LaQuaglia MP, Tolkoff-Rubin NE, Dienstag JL, et al: Impact of hepatitis on renal transplantation. Transplantation 32: 504–507, 1981.

    PubMed  CAS  Google Scholar 

  102. Alter HJ, Hoofnagle JH: Non-A, non-B: Observations on the first decade, in Vyas GN, Dienstag JL, Hoofnagle JH (eds): Viral Hepatitis and Liver Disease. New York, Grune & Stratton, 1984, pp 345–354.

    Google Scholar 

  103. Wyke RJ, Williams R: Clinical aspects of non-A, non-B hepatitis infection. J Virol Methods 2: 17–29, 1980.

    PubMed  CAS  Google Scholar 

  104. Starzl TE, Demetris AJ, Van Thiel DH: Liver transplantation: Part II. N Engl J Med 321: 1092–1099, 1989.

    PubMed  CAS  Google Scholar 

  105. Wright TL, Lake JR: Liver transplantation for patients with hepatitis B; what have we learned from our results?. Hepatology 13: 796–799, 1991.

    PubMed  Google Scholar 

  106. Todo S, Demetris AJ, Van Thiel D, et al: Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 13: 619–626, 1991.

    PubMed  CAS  Google Scholar 

  107. Yoffe B, Burns DK, Bhatt HS, et al: Extrahepatic hepatitis B virus DNA sequences in patients with acute hepatitis B infection. Hepatology 12: 188–192, 1990.

    Google Scholar 

  108. Feray C, Zignego AL, Samuel D, et al: Persistent hepatitis B virus infection of mononuclear blood cells without concomitant liver infection: The liver transplantation model. Transplantation 49: 1155–1158, 1991.

    Google Scholar 

  109. Samuel D, Bismuth A, Mathieu D, et al: Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 337: 813–815, 1991.

    PubMed  CAS  Google Scholar 

  110. Miller RH, Kaneko S, Chung CT, et al: Compact organization of the hepatitis B virus genome. Hepatology 9: 322–327, 1989.

    PubMed  CAS  Google Scholar 

  111. Farza H, Salmon AM, Hadchouel M, et al: Hepatitis B surface antigen gene expression is regulated by sex steroids and glucocorticoids in transgenic mice. Proc Natl Acad Sci USA 84: 1187–1191, 1987.

    PubMed  CAS  Google Scholar 

  112. Demetris AJ, Jaffe R, Sheahan DG, et al: Recurrent hepatitis B in liver allograft recipients: Differentiation between viral hepatitis B and rejection. Am J Pathol 125: 161–172, 1986.

    PubMed  CAS  Google Scholar 

  113. Davies SE, Portman BC, O’Grady JG, et al: Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 13: 150–157, 1991.

    PubMed  CAS  Google Scholar 

  114. Carey W, Pimentel R, Westveer MK, et al: Failure of hepatitis B immunization in liver transplant recipients: Results of a prospective trial. Am J Gastroenterol 85: 1590–1592, 1990.

    PubMed  CAS  Google Scholar 

  115. Rakela J, Wooten RS, Batts KP, et al: Failure of interferon to prevent recurrent hepatitis infection in hepatic allograft. Mayo Clin Proc 64: 429–432, 1989.

    PubMed  CAS  Google Scholar 

  116. Neuhaus P, Steffen R, Blumhardt G, et al: Experience with immunoprophylaxis and interferon therapy after liver transplantation in HBsAg positive patients. Transplant Proc 23: 1522–1524, 1991.

    PubMed  CAS  Google Scholar 

  117. Lauchart W, Muller R, Pichlmayr R: Immunoprophylaxis of hepatitis B reinfection in recipients of human liver allografts. Transplant Proc 19: 2387–2389, 1987.

    PubMed  CAS  Google Scholar 

  118. Lauchart W, Muller R, Pichlmayr R: Long-term immunoprophylaxis of hepatitis B virus reinfection in recipients of human liver allografts. Transplant Proc 19: 4051–4053, 1987.

    PubMed  CAS  Google Scholar 

  119. Mora NP, Klintmalm GB, Poplawski SS, et al: Recurrence of hepatitis B after transplantation: Does hepatitis B immunoglobulin modify the recurrent disease?. Transplant Proc 22: 1547–1548, 1990.

    Google Scholar 

  120. Calmus Y, Hannoun L, Dousett B, et al: HLA class I matching is responsible for the hepatic lesions in recurrent viral hepatitis B after liver transplantation. Transplant Proc 22: 2311–2313, 1990.

    PubMed  CAS  Google Scholar 

  121. Ottobrelli A, Marzano A, Smedile A, et al: Patterns of hepatitis delta virus reinfection and disease in liver transplantation. Gastroenterology 101: 1649–1655, 1991.

    PubMed  CAS  Google Scholar 

  122. Read AE, Donegan E, Lake J, et al: Hepatitis C in patients undergoing liver transplantation. Ann Intern Med 114: 282–284, 1991.

    PubMed  CAS  Google Scholar 

  123. Martin P, Munoz SJ, Di Bisceglie AM, et al: Recurrence of hepatitis C infection following orthotopic liver transplantation. Hepatology 13: 719–721, 1991.

    PubMed  CAS  Google Scholar 

  124. Wright TL, Hsu H, Greenberg H, et al: Recurrence of hepatitis C viral (HCV) infection and disease following liver transplantation (OLTx). Gastroenterology 100: 812, 1991 (abstract).

    Google Scholar 

  125. Poterucha J, Rakela J, Tarwell H, et al: Diagnosis of chronic hepatitis C after liver transplantation using polymerase chain reaction. Gastroenterology 100: 786, 1991, (abstract).

    Google Scholar 

  126. Chung RT, Katkov WN, Dienstag JL, et al: Dynamics of hepatitis C viremia in patients before and after orthotopic liver transplantation. Gastroenterology 100: 730, 1991 (abstract).

    Google Scholar 

  127. Wright TL, Donegan E, Hsu HH, et al: Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 103: 317–322, 1992.

    PubMed  CAS  Google Scholar 

  128. Shah G, Demetris AJ, Gavaler JS, et al: Incidence, prevalence, and clinical course of hepatitis C following liver transplantation. Gastroenterology 103: 323–329, 1992.

    PubMed  CAS  Google Scholar 

  129. Pereira BJG, Millord EL, Kirkman RL, et al: Transmission of hepatitis C virus by organ transplantation. N Engl J Med 325: 254–260, 1991.

    Google Scholar 

  130. Tzakis AG, Arditi M, Whitington PF, et al: Aplastic anemia complicating orthotopic liver transplantation for non-A, non-B hepatitis. N Engl J Med 319: 393–396, 1988.

    PubMed  CAS  Google Scholar 

  131. Davis GL, Balart LA, Schiff ER, et al: Treatment of chronic hepatitis C with recombinant interferon alfa: A multicenter randomized, controlled trial. N Engl J Med 321: 1501–1506, 1989.

    PubMed  CAS  Google Scholar 

  132. Wright TL, Ferrell L, Lake J, et al: Hepatitis C viral RNA in patients on interferon (IFN)-alfa for post-liver transplant (OLTx) hepatitis. Gastroenterology 102: A911, 1992 (abstract).

    Google Scholar 

  133. Sutnick AI, London WT, Blumberg BS, et al: Austalia antigen (a hepatitis associated antigen) in leukemia. J Natl Cancer Inst 44: 1241–1249, 1970.

    PubMed  CAS  Google Scholar 

  134. Sutnick AI, Levine PH, London WT, et al: Frequency of Australia antigen in patients with leukemia in different countries. Lancet 1: 1200–1202, 1971.

    PubMed  CAS  Google Scholar 

  135. Grange MJ, Erlinger S, Teilletd F, et al: A possible relationship to treatment between hepatitis-associated antigen and chronic persistent hepatitis in Hodgkin’s disease. Gut 14: 433–437, 1973.

    PubMed  CAS  Google Scholar 

  136. Wands JR, Chura CM, Roll FJ, et al: Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 68: 105–112, 1975.

    PubMed  CAS  Google Scholar 

  137. Wands JR, Walker JA, Davis TT, et al: Hepatitis B in an oncology unit. N Engl J Med 291: 1371–1375, 1974.

    PubMed  CAS  Google Scholar 

  138. Schulman AN, Fagen ND, Brezina M, et al: HBe-antigen in the course and prognosis of hepatitis B infection: A prospective study. Gastroenterology 78: 253–258, 1980.

    PubMed  CAS  Google Scholar 

  139. Trinchet JC, Beugrand M, Hecht Y, et al: Hépatite fulminante à virus B survenue au cours d’un traitement immunolodepresseur. Gastroenterol Clin Biol 4: 59–62, 1980.

    PubMed  CAS  Google Scholar 

  140. Hoofnagle JH, Dusheiko GM, Schafer DF, et al: Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 96: 447–449, 1982.

    PubMed  CAS  Google Scholar 

  141. Vergani D, Locasciulli A, Masera G, et al: Histological evidence of hepatitis-B-virus infection with negative serology in children with acute leukemia who develop chronic liver disease. Lancet 1: 361–364, 1982.

    PubMed  CAS  Google Scholar 

  142. Wade JC, Gaffey M, Wiernik PH, et al: Hepatitis in patients with acute nonlymphocytic leukemia. Am J Med 75: 413–422, 1983.

    PubMed  CAS  Google Scholar 

  143. Locasciulli A, Santamaria M, Masera G, et al: Hepatitis B virus markers in children with acute leukemia: The effect of chemotherapy. J Med Virol 15: 29–33, 1985.

    PubMed  CAS  Google Scholar 

  144. Cowan DH, Kouroupis GM, Leers W-D: Occurrence of hepatitis and hepatitis B surface antigen in adult patients with acute leukemia. Can Med Assoc J 112: 693–697, 1975.

    PubMed  CAS  Google Scholar 

  145. Sauerbruch T, Frosner G, Theml H, et al: Hepatitis B-virus-marker and rotelnantikorper bei patienten mit hodgkin-non-hodgkin-lymphomen and allgemein internisitischen erkrankungen. Blut 40: 259–266, 1980.

    PubMed  CAS  Google Scholar 

  146. Tabor E, Gerety RJ, Mort M, et al: Prevalence of hepatitis B in a high risk setting: A serologic study of patients and staff in a pediatric oncology unit. Pediatrics 61: 711–715, 1978.

    PubMed  CAS  Google Scholar 

  147. Weitberg AG, Weitzman SA, Watkins E, et al: Immunogenecity of hepatitis B vaccine in oncology patients receiving chemotherapy. J Clin Oncol 3: 718–722, 1985.

    PubMed  CAS  Google Scholar 

  148. Schulman AN, Fagen ND, Ling CM, et al: Repeated type B hepatitis infections: Ten cases studied prospectively. Gastroenterology 72: 1182, 1977 (abstract).

    Google Scholar 

  149. Lightdale CJ, Ikram H, Pinsky C: Primary hepatocellular carcinoma with hepatitis B antigenemia: Effects of chemotherapy. Cancer 46: 1117–1122, 1980.

    PubMed  CAS  Google Scholar 

  150. Steinberg SC, Alter HJ, Leventhal BG: The risk of hepatitis transmission to family contacts of leukemia patients. J Pediatr 87: 753–757, 1975.

    PubMed  CAS  Google Scholar 

  151. Wands JR: Subacute and chronic active hepatitis after withdrawal of chemotherapy (letter). Lancet 2: 979, 1975.

    PubMed  CAS  Google Scholar 

  152. Thung SN, Gerber MA, Klion F, et al: Massive hepatic necrosis after chemotherapy withdrawal in a hepatitis B virus carrier. Arch Intern Med 145: 1313–1314, 1985.

    PubMed  CAS  Google Scholar 

  153. Malone W, Novak R: Outcome of hepatitis in children with acute leukemia. Am J Dis Child 134: 584–587, 1980.

    PubMed  CAS  Google Scholar 

  154. Locasciulli A, Alberti A, Barbieri R, et al: Evidence of non-A, non-B hepatitis in children with acute leukemia and chronic liver disease. Am J Dis Child 173: 354–356, 1983.

    Google Scholar 

  155. Barton JB, Conrad ME: Beneficial effects of hepatitis in patients with acute myelogenous leukemia. Ann Intern Med 90: 188–190, 1979.

    PubMed  CAS  Google Scholar 

  156. Foon KA, Yale C, Clodfelter K, et al: Posttransfusion hepatitis in acute myelogneous leukemia: Effect on leukemia. JAMA 244: 1806–1807, 1980.

    PubMed  CAS  Google Scholar 

  157. Rotoli B, Formisano S, Martinelli V: Long-term survival in acute myelogenous leukemia complicated by chronic active hepatitis (letter). N Engl J Med 307: 1712–1713, 1982.

    PubMed  CAS  Google Scholar 

  158. Cacciola E, Giustolisi R: Acute myelogenous leukemia and hepatitis (letter). Ann Intern Med 92: 127–128, 1980.

    PubMed  CAS  Google Scholar 

  159. Brody SA, Russell WG, Krantz SB, et al: Beneficial effect of hepatitis in leukemic reticuloendotheliosis. Arch Intern Med 141: 1080–1081, 1981.

    PubMed  CAS  Google Scholar 

  160. Shepard KV, Levin B, Faintuch J, et al: Hepatitis as a beneficial prognostic factor in patients receiving intra-arterial chemotherapy for metastatic colorectal carcinoma. Clin Res 31: 779A, 1983 (abstract).

    Google Scholar 

  161. Rosner F: Hepatitis and leukemia (letter). Ann Intern Med 90: 853, 1979.

    PubMed  CAS  Google Scholar 

  162. van den Ouweland FA, Holdrinet RSG, de Pauw BE, et al: Transaminase, hepatitis B, and prognosis in acute non-lymphoblastic leukemia (letter). N Engl J Med 309: 990, 1983.

    PubMed  Google Scholar 

  163. Julia A, Font L: Hepatitis and leukemia (letter). Ann Intern Med 93: 780, 1980.

    PubMed  CAS  Google Scholar 

  164. Carmichael GP, Zahradnik JM, Moyer GH, et al: Adenovirus hepatitis in an immunosuppressed adult patient. Am J Clin Pathol 71: 352–355, 1979.

    PubMed  Google Scholar 

  165. Katz ME, Cassileth PA: Hyperbilirubinemia during induction therapy of acute granulocytic leukemia. Cancer 40: 1390–1392, 1977.

    Google Scholar 

  166. De Cock KM, Niland JC, Lu HP, et al: Experience with human immunodeficiency virus infection in patients with hepatitis B virus and hepatitis delta virus infections in Los Angeles. Am J Epidemiol 127: 1250–1260, 1988.

    PubMed  Google Scholar 

  167. Trent Mills C, Lee E, Perrillo R: Relationship between histology, aminotransferase levels, and viral replication in chronic hepatitis B. Gastroenterology 99: 519–524, 1990.

    Google Scholar 

  168. Rector WG, Govindarajan S, Horsburgh CR, et al: Hepatic inflammation, hepatitis B replication, and cellular immune function in homosexual males with chronic hepatitis B and antibody to human immunodeficiency virus. Am J Gastroenterol 83: 262–266, 1988.

    PubMed  Google Scholar 

  169. Bonacini M: Hepatobiliary complications in patients with human immunodeficiency virus infection. Am J Med 92: 404–411, 1992.

    PubMed  CAS  Google Scholar 

  170. Seto E, Benedict Yen TS, Matija Peterlin B, et al: Transactivation of the human immunodeficiency virus long terminal repeat by the hepatitis B virus X protein. Proc Natl Acad Sci USA 85: 8286–8290, 1988.

    PubMed  CAS  Google Scholar 

  171. McDonald JA, Caruso L, Karayiannis P, et al: Diminished responsiveness of male homosexual chronic hepatitis B carriers with HTLV-III antibodies to recombinant alfa-interferon. Hepatology 4: 719–723, 1987.

    Google Scholar 

  172. Novick DM, Farci P, Croxson TS, et al: Hepatitis D virus and human immunodeficiency virus antibodies in parenteral drug abusers who are hepatitis B surface antigen positive. J Infect Dis 158: 795–803, 1988.

    PubMed  CAS  Google Scholar 

  173. Salomon RE, Kaslow RA, Phair JP, et al: Human immunodeficiency virus and hepatitis delta virus in homosexual men. A study of four cohorts. Ann Intern Med 108: 51–54, 1988.

    Google Scholar 

  174. Martin P, Di Bisceglie AM, Kassianides C, et al: Rapidly progressive non-A, non-B hepatitis in patients with human immunodeficiency virus infection. Gastroenterology 97: 1559–1561, 1989.

    PubMed  CAS  Google Scholar 

  175. Public Health Laboratory Service Survey: Hepatitis B in retreat from dialysis units in United Kingdom in 1973. Br Med J 1: 1579–1581, 1976.

    Google Scholar 

  176. Postic B, Schreiner DP, Hanchett JE, et al: Containment of hepatitis B virus infection in a hemodialysis unit. J Infect Dis 138: 884–889, 1978.

    PubMed  CAS  Google Scholar 

  177. Najem GR, Louria DB, Thind IS, et al: Control of hepatitis B infection. The role of surveillance and an isolation hemodialysis center. JAMA 245: 153–157, 1981.

    PubMed  CAS  Google Scholar 

  178. Immunization Practices Advisory Committee: Recommendations for protection against viral hepatitis. MMWR 34: 313–324, 329-335, 1985.

    Google Scholar 

  179. Stevens CE, Szmuness W, Goodman AI, et al: Hepatitis B vaccine: Immune response in hemodialysis patients. Lancet 2: 1211–1213, 1980.

    PubMed  CAS  Google Scholar 

  180. Stevens CE, Alter HJ, Taylor PE, et al: Hepatitis B vaccine in patients receiving hemodialysis: Immunogenicity and efficacy. N Engl J Med 311: 496–501, 1984.

    PubMed  CAS  Google Scholar 

  181. Grob PJ, Binswanger U, Zaruba K, et al: Immunogenicity of a hepatitis B subunit vaccine in hemodialysis and in renal transplant recipients. Antiviral Res 3: 43–52, 1983.

    PubMed  CAS  Google Scholar 

  182. Bergamini F, Zanetti AR, Ferroni P, et al: Immune response to hepatitis B vaccine in staff and patients in renal dialysis units. J Infect 7(suppl 1): 35–40, 1983.

    PubMed  Google Scholar 

  183. Crosnier J, Jungers P, Courouce A-M, et al: Randomized placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units. II. Haemodialysis patients. Lancet 2: 797–800, 1981.

    Google Scholar 

  184. Desmyter J, Colaert J, De Groot G, et al: Efficacy of heat-inactivated hepatitis B vaccine in hemodialysis patients and staff: Double-blind placebo-controlled trial. Lancet 2: 1323–1327, 1983.

    PubMed  CAS  Google Scholar 

  185. Desmyter J, Colaert J: Comparative immunogenicity of MSD, Pasteur and CLB hepatitis B vaccines in 245 hemodialysis patients (abst), in Vyas GN, Dienstag JL, Hoofnagle JH (eds): Viral Hepatitis and Liver Disease. New York, Grune & Stratton, 1984, pp 709–710.

    Google Scholar 

  186. Jacobson IM, Jaffers G, Dienstag JL, et al: Immunogenicity of hepatitis B vaccine in renal transplant recipients. Transplantation 39: 393–395, 1985.

    PubMed  CAS  Google Scholar 

  187. Arnold W, Baumann W: Vaccination of children with malignant diseases with alum-absorbed hepatitis B vaccine-Immunogenicity studies. Scand J Infect Dis 38(suppl): 33–36, 1983.

    CAS  Google Scholar 

  188. Dienstag JL, Werner BF, Polk BF, et al: Hepatitis B vaccine in health care personnel: Safety, immunogenicity, and indicators of efficacy. Ann Intern Med 101: 34–40, 1984.

    PubMed  CAS  Google Scholar 

  189. Alper CA, Kruskall MS, Marcus-Bagley D, et al: Genetic prediction of nonresponse to hepatitis B vaccine. N Engl J Med 321: 708–712, 1989.

    PubMed  CAS  Google Scholar 

  190. Katkov WN, Watkins E, Cody H, et al: Immunogenicity of pre-S plus S hepatitis B vaccine in healthy adults. Hepatology 12: 879, 1990 (abstract).

    Google Scholar 

  191. Meuer SC, Dumann H, Meyer zum Buschenfelde KH, et al: Low-dose interleukin-2 induces systemic immune responses against HBsAg in immunodeficient non-responders to hepatitis B vaccination. Lancet 1: 15–18, 1989.

    PubMed  CAS  Google Scholar 

  192. Grob PJ, Joller-Jemelka HI, Binswanger U, et al: IFN as an adjuvant for hepatitis B vaccination in non-and low-responder populations. Eur J Clin Microbiol 3: 195–198, 1984.

    PubMed  CAS  Google Scholar 

  193. Centers for Disease Control: Postexposure prophylaxis of hepatitis B: Recommendations of the Immunization Practices Advisory Committee. Ann Intern Med 101: 351–354, 1984.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gastrointestinal Unit, Medical Services, Massachusetts General Hospital, and Department of Medicine, Harvard Medical School, Boston, Massachusetts, 02114, USA

    Jules L. Dienstag

  2. Division of Gastroenterology, Department of Medicine, UCLA School of Medicine, Los Angeles, California, 90024, USA

    William N. Katkov

Authors
  1. Jules L. Dienstag
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William N. Katkov
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Massachusetts General Hospital, Boston, Massachusetts, USA

    Robert H. Rubin M.D. (Chief of Transplantation Infectious Disease, Director of the Center for Experimental Pharmacology and Therapeutics) (Chief of Transplantation Infectious Disease, Director of the Center for Experimental Pharmacology and Therapeutics)

  2. Division of Health Sciences and Technology, Harvard University-Massachusetts Institute of Technology, Cambridge, Massachusetts, USA

    Robert H. Rubin M.D. (Chief of Transplantation Infectious Disease, Director of the Center for Experimental Pharmacology and Therapeutics) (Chief of Transplantation Infectious Disease, Director of the Center for Experimental Pharmacology and Therapeutics)

  3. Pacific California Medical Center, San Francisco, California, USA

    Lowell S. Young M.D. (Director of Kuzell Institute for Arthritis and Infectious Diseases, Chief of Division of Infectious Diseases) (Director of Kuzell Institute for Arthritis and Infectious Diseases, Chief of Division of Infectious Diseases)

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Plenum Publishing Corporation

About this chapter

Cite this chapter

Dienstag, J.L., Katkov, W.N. (1994). Viral Hepatitis in the Compromised Host. In: Rubin, R.H., Young, L.S. (eds) Clinical Approach to Infection in the Compromised Host. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2490-8_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-2490-8_12

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-306-44617-7

  • Online ISBN: 978-1-4615-2490-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation